Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

948 recalls · Class II, newest first

Class II · Moderate risk

Extended Phenytoin Sodium Capsules

Failed Dissolution Specifications: Out-of-specification results for dissolution (above specification)

Terminated Dissolution failure Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0876-2023
Class II · Moderate risk

Levsin injection

CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Terminated cGMP deviation Viatris Inc NDC 0037-9001-05 D-0866-2023
Class II · Moderate risk

Sodium Chloride 0.9% Injection

Lack of assurance of sterility: The product was potentially exposed to below-recommended storage temperatures, which may cause leaks in the packaging.

Terminated Sterility / contamination Fresenius Medical Care Holdings, Inc. NDC 49230-300-10 D-0777-2023
Class II · Moderate risk

Pain Reliever

Failed Impurities/Degradation Specifications: firm's investigation due to customer complaints for discoloration found that the product was out of specification for an impurity.

Completed Impurity / degradation Aurobindo Pharma USA Inc. NDC 0363-9947-35 D-0765-2023
Class II · Moderate risk

Foaming Hand Sanitizer

CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.

Terminated cGMP deviation Alpha Aromatics D-0760-2023

Recalls by year